Kornimate/medical-research-clean huggingface dataset:
impact of intraperitonael nebulization of local anesthetic on postoperative pain associated with laparoscopic surgery

Conditions: Gynecologic Laparoscopic Surgery

Summary: studies evaluating intraperitoneal local anesthetic instillation for pain relief after laparoscopic procedures have provided conflicting results. this randomized, double-blind study was designed to assess the effects of a novel intraperitoneal local anesthetic administration technique using nebulization on pain relief after gynecologic laparoscopic surgery.

studies evaluating intraperitoneal local anesthetic (la) instillation for pain relief after laparoscopic surgery have provided conflicting results. one of the factors that might contribute to failure of the instillation technique may be related to inadequate distribution of local anesthetic throughout the peritoneal surface. in contrast, nebulization should provide a uniform spread of drugs throughout the peritoneal cavity and thus may be beneficial to improve pain relief after laparoscopic procedures. the investigators reported that a microvibration-based nebulization device (aeroneb pro® system, aerogen, galway, ireland) could be used for ropivacaine delivery into the insufflation gas required to create pneumorpeitoneum. the investigators hypothesized that intraperitoneal ropivacaine nebulization would provide superior pain relief than ropivacaine instillation after gynecologic laparoscopic surgery. this randomized, double blind, controlled clinical trial was designed to assess the analgesic efficacy of ropivacaine nebulization before or after surgery compared with intraperitoneal ropivacaine instillation and placebo after gynecologic laparoscopic procedures.

Eligibility criteria:
inclusion criteria: * females 18-70 years old, asa score 1 - 3; * scheduled for laparoscopic operative surgery in the obstetrics and gynecology unit; * free from pain in preoperative period, without habitual analgesic use; * without cognitive impairment or mental retardation, who gave a written informed consent exclusion criteria: * females under 18 or over 70; * asa 4 or 5; * emergency/urgency criteria, postoperative admission in a intensive care unit with sedation or ventilatory assistance; cognitive impairment or mental retardation; * habitual analgesic use; progressive degenerative diseases of the cns; * convulsions or chronic therapy with antiepileptic drugs; * severe hepatic or renal impairment; * pregnancy or lactation; * allergy to one of the specific substances used in the study; * acute infectious disease or inflammatory chronic disease, alcohol or drug addiction; * any kind of communication problem; * neurologic or psychiatric disease; * no written informed consent

Keywords: gynecologic laparoscopic surgery postoperative pain nebulization ropivacaine
adherence to exclusive enteral nutrition in patients with crohn's disease

Conditions: Crohn Disease

Summary: the study has not yet been completed


Eligibility criteria:
inclusion criteria: * the main inclusion criteria were as follows: had diagnosed cd more than 3 months; had een in the past 6 months; were at least 18 years old; agreed to participate in this study. exclusion criteria: * the exclusion criteria were received treatment from mental health professionals due to any mental or cognitive impairment; suffered from other serious diseases, such as heart, brain, lung, liver and kidney dysfunction; severe infection, anemia, cachexia or other serious complications were found.

Keywords: crohn's disease, exclusive enteral nutrition, adherence
therapeutic potential of myofascial structural integration in children with cerebral palsy

Conditions: Spastic Cerebral Palsy

Summary: the investigators hypothesize that children with spastic cerebral palsy will show greater improvements in gross motor function, associated developmental skills and growth after the 3 months of myofascial structural integration treatment, a form of deep massage, than they showed after a 3- or 6-month pre-treatment waiting period. the investigators further hypothesize that children with spastic cp will maintain their gains in gross motor function for ≥ 3 months after completion of msi treatment.

* the investigators will talk to you by telephone to determine if your child is eligible for the study. * the study lasts for a total of 12 months with the massage treatment period lasting 12 weeks. * the study entails a total of 10 sessions of myofascial structural integration therapy over the 12-week period. each session will last one hour. * the child will have an evaluation of motor functions and development on enrollment and at three-month intervals for a total of 5 evaluations.

Eligibility criteria:
inclusion criteria: * children from 1 up to, but not including, 7 years of age * children having the diagnosis of spastic cerebral palsy * children who have spasticity in one or both upper or lower limbs * children who are classified as either gross motor function classification system (gmfcs) level 2, 3 or 4 or manual ability classification system (macs) level 2, 3, 4 or 5 exclusion criteria: * children with active seizure disorders * children taking more than one medication to control their seizures * children with severe health problems that could be exacerbated by the treatment (such as severe chronic lung disease) * children who have undergone surgical treatments or botulinum injections within 6 months of entering the study * children who have planned surgical interventions during the studies time course * children with sensory, cognitive or language deficits which would affect their ability to understand directions necessary for assessment.

Keywords: spasticity cerebral palsy hemiplegia hemiparesis diplegia paraplegia quadriplegia quadriparesis
assessment of proenkephalin to detect acute kidney injury (aki)

Conditions: Heart Failure; Volume Overload; Decompensated Heart Failure; Systolic Heart Failure

Summary: researchers are observing the values of proenkephalin (penk) via a blood draw in hospitalized patients that are volume overloaded requiring diuresis. if changes in penk are found, physicians may predict values of change in kidney function during treatment.

the purpose of this study will be to probe if values of proenkephalin, called penk in this proposal, can identify those patients who develop aki. this biomarker is an opioid that is rapidly released in response to renal injury. at a cut-off value of 100pmol/l, it has been reported to have excellent sensitivity and specificity for detecting renal injury. penk has been shown to be prognostic of wrf and outcomes in patients with acute heart failure but requires evaluation of efficacy in detecting aki in standard of care clinical practice settings. in this study we propose to evaluate the baseline presence of plasma and/or serum levels of biomarkers of renal injury and changes in these biomarkers during the course of in-hospital intravenous diuretic therapy. the question is if threshold values of the biomarkers can be identified and if those threshold values would indicate a clinically significant change in renal function that would warrant a change in diuretic therapy to occur. in this context the quantitative assessment of intravascular volume will provide objective corroboration as to volume status in relation to biomarker levels and changes during treatment. if this approach can be proven to be fruitful, it would be anticipated that a subsequent study, a clinical trial, to test the hypothesis that biomarkers of aki, specifically penk, could be used to identify and avoid aki in hospitalized patients with decompensated hf.

Eligibility criteria:
inclusion criteria: * age \> 18 years * lvef \<50% measured within 6 months of index hospitalization * clinically identified volume overload with at least one sign of volume overload (pre-admission fluid weight gain, edema, increased doe, pnd, orthopnea, jvd on examination) and a need for intravenous diuretic therapy exclusion criteria: * baseline scr \>3.0mg/dl and k+ \ 5.5meq/l * hemoglobin \< 9.0g/dl * systemic systolic blood pressure consistently \<100mm hg * patients being treated with hemodialysis, ckd stage 5 or s/p renal transplantation * s/p cardiac transplant or lvad implantation/total artificial heart * pregnancy or of child bearing potential * allergy to iodine * unable to provide informed consent to participate in the study
albumin bilirubin index as a predictor of outcome of variceal bleeding

Conditions: Prediction of Variceal Bleeding

Summary: albumin bilirubin index as a predictor of outcome of variceal bleeding

this study is to clarify the predictive value of albumin bilirubin index for recurrent bleeding within 3 month after endoscopic treatment in patients with cirrhosis and egvb

Eligibility criteria:
inclusion criteria: * age between 18-80 years old exclusion criteria: * hcc hematological disease
bleb vascularity and the outcomes after trabeculectomy

Conditions: Glaucoma; Filtering Bleb

Summary: 1. study objective: to evaluate the relationship between filtering bleb vascularity and the surgical outcomes after trabeculectomy 2. study design: a prospective study of 51 eyes of 44 patients after primary mmc-augmented trabeculectomy. the follow-up was 12 months.

total vessel area of a filtering bleb was measured with imagej software on colour photographs of a filtering bleb on day 1, 14, 1, 3 and 6 months and 1 year after trabeculectomy. blebs were classified clinically as successful (iop below 18 mmhg and a \>30% reduction in iop without antiglaucoma medications or additional surgical interventions) or failed. linear regression analysis was performed to determine the correlation of the bleb vascularity with iop.

Eligibility criteria:
inclusion criteria: * primary open angle glaucoma (poag) with medically uncontrolled intraocular pressure (iop) * pseudoexfoliation glaucoma (pexg) with medically uncontrolled intraocular pressure (iop) exclusion criteria: * primary angle closure glaucoma (pacg) * secondary glaucoma except pexg * previous eye surgery * subjects with decreased vision due to other reasons than glaucoma (e.g., exudative age-related macular degeneration (amd), proliferative diabetic retinopathy, inflammatory eye diseases)

Keywords: filtering bleb trabeculectomy glaucoma
physiological and clinical changes in nhf therapy

Conditions: Chronic Obstructive Pulmonary Disease; Hypercapnia; Interstitital Lung Disease

Summary: the study explores the changes in pressure, volume and in hypercapnia in patients with copd and ild. the investigators will use different application forms.


Eligibility criteria:
inclusion criteria: * copd, ild exclusion criteria: * unstable disease

Keywords: nasal high flow
chaco study: control of arterial hypertension in colombian patients

Conditions: Hypertension

Summary: epidemiological study (cross-sectional study) in order to determine the patients who present an adequate control of the blood pressure (bp), in a population of colombian patients diagnosed with arterial hypertension (ah) and who are under pharmacological treatment.

objective: to determine the proportion of patients who present an adequate control of the blood pressure (bp), in a population of colombian patients diagnosed with arterial hypertension (ah) and who are under pharmacological treatment. materials and methods: epidemiological study (cross-sectional study), multicentre type, in patients older than 18 years with prior diagnosis of ah in colombia. the blood pressure control will be evaluated as the main variable (only one single blood pressure check in the doctor's office). other secondary variables to evaluate are: demographical analysis, type (s) of antihypertensive treatment (s) used in patients, level of bp control, adverse events associated with antihypertensive treatment, comorbidities and risk factors, adherence, perception about the possible benefits of the use of combined therapy in "mono-tablet" versus "multi-tablet". the analysis will be carried out from two perspectives: a first descriptive approach and a second analytical approach, with a level of significance of 5%.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * prior diagnosis of arterial hypertension (ah) ≥ 3 months before * patients who are under pharmacological treatment of ah ≥ 3 months before exclusion criteria: * the patient has rejected the participation in the study. * patients who, in the judgment of the investigator, do not understand or are not willing to adequately answer the questions. * mental or psychiatric illness that, in the judgment of the investigator, does not allow adequate information to be obtained.
endoscopic full thickness biopsy, gastric wall.

Conditions: Gastroparesis

Summary: the proposed study will assess the efficacy and safety of the innovative endoscopic technique for the acquisition of full thickness gastric muscle wall biopsies. having access to full thickness biopsies will allow an increased understanding of the pathophysiology of gastrointestinal diseases such as functional gastrointestinal disorders, gastroparesis, pseudoobstruction and other motility disorders. this information is essential to development of more targeted and effective therapy than currently available. despite the high prevalence of functional gastrointestinal disorders and its significant impact on social and health care costs, the underlying cause is not well understood and there is no effective specific treatment to successfully alleviate patient symptoms.

our group has studied a new endoscopic method using a submucosal endoscopy with mucosal flap (semf) technique to acquire full thickness gastric tissues successfully and safely in preclinical studies. the proposed study will assess the efficacy and safety of the innovative endoscopic technique for the acquisition of full thickness gastric muscle wall biopsies. having access to full thickness biopsies will allow an increased understanding of the pathophysiology of gastrointestinal diseases such as functional gastrointestinal disorders, gastroparesis, pseudoobstruction and other motility disorders. this information is essential to development of more targeted and effective therapy than currently available. despite the high prevalence of functional gastrointestinal disorders and its significant impact on social and health care costs, the underlying cause is not well understood and there is no effective specific treatment to successfully alleviate patient symptoms.

Eligibility criteria:
inclusion criteria: 1. symptomatic refractory idiopathic gastroparesis: 1. the refractory nature of symptoms (e.g. based on nutritional failure, consideration for enteral or parenteral nutrition) will be determined by the physician/gastroenterologist who is the primary care provider for the patient's gastroparesis. 2. patients will have documentation within the last 2 years of delayed gastric emptying with \>30% retained gastric contents at 4 hours based on 296 kcal solid-liquid, fat-containing standard meal gastric emptying test. 3. the patient's physician will determine if this procedure may potentially provide prognostic and therapeutic options. 2. age \> 18 and \< 70 years old 3. hemoglobin (hb) \> 10g, platelets \>150,000 and prothrombin time- international normalized ratio (inr) \<1.5 4. ability to give informed consent exclusion criteria: 1. prior oropharyngeal, esophageal, gastric or small bowel surgery 2. esophageal stricture 3. prior abdominal radiation therapy 4. prior feeding tube placement 5. coagulopathy 6. use of coumadin or anti-platelet drugs e.g. plavix, steroids or immunosuppressive drugs 7. pregnancy -
effect of aerobic exercise on polycystic ovary syndrome

Conditions: Polycystic Ovary Syndrome

Summary: the development of polycystic ovary syndrome has been linked to chronic low-grade inflammation (pcos). in this context, the current study looked into the effects of aerobic exercise on il6, tnf, and c-reactive protein (crp) in pcos women. this was a randomized clinical trial including 40 females diagnosed with pcos who were between the ages of 25 and 35. the participants were divided into two groups, each with an equal number of individuals: aerobic exercise (aem) and metformin (m). at baseline and after 12 weeks of intervention, participants' levels of il6, tnf, and crp were measured.


Eligibility criteria:
inclusion criteria: * mean age of 26.7 ± 2.3, body mass index (bmi) 23.6±3.5 kg/m2) . * confirmation by medical history of hyperandrogenic oligo amenorrhea (\<8 menses per year) * pco on ultrasonography of more than 10 ovarian follicles 2-9 mm in diameter exclusion criteria: * disorders known to cause hyperandrogenisms, such as congenital adrenal hyperplasia, thyroid dysfunction, and hyperprolactinemia. * renal or hepatic dysfunction
enzastaurin for patients with metastatic colorectal cancer

Conditions: Colonic Neoplasms

Summary: enzastaurin given daily to participants with colorectal cancer who have stage 4 disease and have not received prior chemotherapy for advanced colorectal cancer


Eligibility criteria:
inclusion criteria: * diagnosed with colorectal cancer that is advanced or metastatic (has spread to other parts of the body); able to visit the doctor's office every 28 days for at least 6 months; able to swallow tablets exclusion criteria: * women cannot be pregnant or breastfeeding; no history of significant heart disease or any other significant medical problems as determined by the participant's physician
acute exposure of simulated hypoxia on blood and tissue oxygenation (abga, nirs)

Conditions: Pulmonary Hypertension

Summary: randomized crossover trial in patients with pulmonary arterial hypertension (pah) and chronic thromboembolic pulmonary hypertension (cteph) to assess the acute response to simulated altitude (fio2:15.1, equivalent to 2500m above sea level) on blood and tissue oxygenation (abga, near infrared spectroscopy)

low altitude baseline measurements will be performed in zurich (460m asl) including echocardiography, right heart catheterization, six-minute walk test (6mwt), pulmonary function test, clinical assessment and blood gas analysis. randomly assigned to the order of testing, the participants will be tested under simulated altitude (fio2: 15.1% with the "amc altitrainer") and shamed altitude with the same device. at rest and under exercise data from abga and near infrared spectroscopy will be compared under simulated altitude and shamed altitude.

Eligibility criteria:
inclusion criteria: * informed consent * ph diagnosed according to internation guidelines: mean pulmonary artery pressure (mpap) ≥ 25 mmhg along with a pulmonary artery wedge pressure (pawp) ≤15 mmhg during right heart catheterization at the time of initial diagnosis * ph class 1 (pah) or 4 (cteph) * stable condition, on the same medication for \> 4 weeks * patient live permanently at an altitude \< 1000m asl. exclusion criteria: * resting partial oxygen pressure (pao2) ≤7.3 kilopascal (kpa) corresponding to the requirement of long-term oxygen therapy \> 16hour daily (nocturnal oxygen therapy alone is allowed) * severe daytime hypercapnia (pco2 \> 6.5 kpa) * susceptibility to high altitude related diseases (ams, high-altitude pulmonary edema (hape), etc.) based on previous experienced discomfort at altitudes. * exposure to an altitude \>1500m for ≥3 nights during the last 4 weeks before the study participation * residence \> 1000m above sea level * inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, neurological or orthopedic problems with walking disability * women who are pregnant or breast feeding

Keywords: simulated altitude arterial blood gas analysis near infrared spectroscopy
a phase i, open-label, single-center study to assess the absorption, metabolism, and excretion of [14c]-azd3293

Conditions: Healthy Volunteers; Mass Balance Study

Summary: this study will be an open-label, non-randomized, absorption, metabolism, and excretion study to evaluate the mass balance, metabolite profiles, and rates and routes of elimination of \[14c\]-azd3293 and derived metabolites following administration as a single 100-mg (containing approximately 150 µci) oral dose (as an oral solution)

this study will be an open-label, non-randomized,absorption, metabolism, and excretion study to evaluate the mass balance, metabolite profiles, and rates and routes of elimination of \[14c\]-azd3293 and derived metabolites following administration as a single 100-mg (containing approximately 150 µci) oral dose (as an oral solution) following at least an 8-hour fast from food (not including water). seven healthy male subjects will be enrolled in the study at a single study site to complete a minimum of 6 subjects. the study will consist of 2 visits.

Eligibility criteria:
inclusion criteria: healthy male subjects between 18 and 55 years of age, inclusive, at the time of consent with suitable veins for cannulation or repeated venipuncture; 2) body weight between 50 to 100 kg, inclusive; 3) within bmi range 19 to 30 kg/m2, inclusive; 4) in good health, as determined by no clinically significant findings from medical history, physical examination with neurological examination, 12-lead ecg, and vital signs as judged by the investigator; - exclusion criteria: participation in any prior study of azd3293 or previous enrollment in the present study; 2) significant history or clinical manifestation of any metabolic, allergic, dermatological, hepatic, renal, hematological, pulmonary, cardiovascular, gi, neurological, or psychiatric disease or disorder which, in the opinion of the investigator, may either put the subject at risk because of participation in the study, interfere with absorption, distribution, metabolism or excretion of drugs, or influence the results or the subject's ability to participate in the study; 3) history of significant hypersensitivity, intolerance, or allergy to any drug compound, food, or other substance, unless approved by the investigator; -

Keywords: beta secretase inhibitor alzheimer disease
familial dysglobulinemia

Conditions: Dysglobulinemia

Summary: multiple myeloma (mm) is a malignant proliferation of monoclonal plasma cells. myeloma accounts for almost 14% of all hematologic cancers and is essentially incurable. myeloma commonly evolves from a precursor disease, monoclonal gammopathy of undetermined significance (mgus). despite intensive study, the etiology of mgus and myeloma are unknown and no lifestyle or environmental exposure factors have been identified that are consistently linked to increased risk of mm, mgus or the transition between the two. the overall goal is to identify risk genes for dysglobulinemia, and more specifically multiple myeloma. this will involve the conservation of cells in a bank and genetic sequencing on samples obtained from families with at least two cases of dysglobulinemia. material used for sequencing is likely to include fresh peripheral blood cells or lymphoblastoid lines established from peripheral blood lymphocytes of patients.


Eligibility criteria:
inclusion criteria: * 2 cases per family at least * 1 case alive at least * biological material available for 1 case at least * patients give their informed consent * attached to the french health protection service exclusion criteria: * age under 18

Keywords: dysglobulinemia multiple myeloma mgus waldenström genetic factors sequencing